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CytotoxicityA novel bimetallic Fe(III) complex with the bis(triaza-cyclononane) ligand 2,6-bis(1,4,7-triazacyclonon-1-
ylmethyl)-4-methylphenol (bcmp) is reported. [Fe2{bcmp(-H)}(l-OH)Cl2]Cl2 (2) contains two octahedral
Fe(III) centers bound to the two triaza-cyclononane rings of bcmp. The coordination sphere is completed
by one chlorine, one bridging phenolate oxygen and one bridging hydroxide group. The complex has been
characterized by elemental analysis, Mössbauer spectroscopy, UV–Vis spectroscopy, pH potentiometric
titration, ESI mass spectrometry and cyclic voltammetry. The complex hydrolyzes the DNA model bis
(2,4-dinitrophenyl) phosphate (BDNPP) with a maximum activity a pH 7. Michaelis–Menten behavior
is observed with kcat = 3.56  104 s1 and Km = 0.56 mM (pH 7.0, 40 C). The interaction of 2 with CT
DNA was studied by electronic absorption spectroscopy and gel electrophoresis. Notably, the complex
relaxes supercoiled pUC19 DNA into the nicked form at low micromolar concentration (10 lM) in the
presence of an external reducing agent (ascorbic acid). Finally, the in vitro antiproliferative activity of 2
was assessed on a panel of human cancer cell lines and results revealed that the complex exhibited a
significant cytotoxic effects in particular versus colon LoVo cancer cells, wih IC50 value 2.5 times lower
than that shown by the reference metallodrug cisplatin (3.54 versus 8.53 lM).
 2016 Elsevier B.V. All rights reserved.1. Introduction
Hydrolases are an important class of enzymes which catalyze
hydrolysis reactions of several kinds of substrate [1] such as
peptidases (peptide bonds) [2], ureases (urea) [3], purple acid
phosphatase (phosphate monoesters) [4], phosphotriesterases
(phosphotriesters) [5] and DNA/RNA polymerases (DNA and RNA)
[6]. A common feature of most of the enzymes belonging to this
important family is the presence of two metals in the active site,
mainly Mg(II), Zn(II), Fe(II, III) and Mn(II) which can operate coop-
eratively. Several examples of bimetallic complexes are reported in
the literature which are able to mimic the natural enzymes and
catalyze hydrolysis reactions [7]. A precise spatial orientation of
the two metal ions is a fundamental aspect to take into considera-
tion while designing an artificial metallo-hydrolase. The two metal
ions in the active site of an artificial hydrolase can be the same(homo-nuclear complexes) or two different metals (hetero-nuclear
complexes) or can have different oxidation states, mainly +2 and
+3. Our group is particularly interested in one class of this large
family of enzymes, namely metallo-nucleases which are able to
hydrolyze the phosphodiester bonds of DNA and RNA [8]. It is well
known that the phosphate diester linkages in DNA are extremely
resistant to spontaneous hydrolysis; the half-life for the hydrolysis
of a phosphate diester bond in DNA at neutral pH and 25 C is more
than hundreds of thousands years [9]. Such hydrolytic inertness,
which ensures the preservation of the genetic information, makes
DNA manipulation quite difficult. In vivo, DNA is manipulated by
nucleases or restriction enzymes, which efficiently catalyze DNA
scission in a sequence-specific manner [10]. Nucleases are able to
accelerate the hydrolysis of the phosphate diester bonds in the
DNA backbone up to 1016-fold, thus making the DNA manipula-
tions that are essential for life possible. Artificial metallonucleases,
metal complexes that catalyze phosphate diester hydrolysis and
mimic the function of nucleases can be employed as biomimetic
systems to elucidate the mechanisms of the natural enzymes. We
recently reported two bimetallic complexes, a dinuclear Cu(II)
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ylmethyl)-4-methylphenol (bcmp) which showed interesting
biological properties such as DNA cleavage activity and in vitro
cytotoxicity against different cancer cell lines [11,12]. These previ-
ous results triggered our interest in replacing Cu(II) and Zn(II) with
a metal in a higher oxidation state such as Fe(III). We anticipated
that the higher positive charge would lead to a stronger binding
interaction with the negatively charged phosphate diester back-
bone of DNA and thus to a higher biological activity [13,14]. Fur-
thermore, a recent paper published by Neves and co-workers
showed that a bimetallic complex based on two Fe(III) ions is able
to cleave DNA and catalyze the oxidation of catechol [15]. Herein
we report the synthesis, full characterization, DNA interaction
and cytotoxic properties of the new dinuclear Fe(III) complex
[Fe2{bcmp(-H)}(l-OH)Cl2]Cl2 (2).2. Experimental
2.1. Materials and instruments
FeCl36H2O was purchased from TCI Europe. All the other chem-
icals and solvents were of analytical or spectroscopic grade,
obtained from commercial sources and used without further purifi-
cation. All the solvents were obtained from Apollo Scientific. Bcmp
(1) [11] and bis(2,4-dinitrophenyl) phosphate (BDNPP) [16] were
prepared following the literature procedures. UV–Vis measure-
mentswere carried out on a Varian Cary 50 scan spectrophotometer
coupled to a Grant thermostatted water circulation bath. Elemental
analyses (carbon, hydrogen and nitrogen) were performed with a
PerkinElmer 2400 series II analyzer. ESI mass spectra were recorded
in negative mode with a Waters LCT Premier XE Spectrometer.
Room Temperature Mössbauer spectroscopy (RT-MS) was per-
formed by using a conventional constant acceleration spectrome-
ter, using a 57Fe source, nominal strength 1850 MBq in a Rh matrix.
2.2. Synthesis
2.2.1. [Fe2{bcmp(-H)}(l-OH)Cl2]Cl2 (2)
The complex was obtained by adding dropwise a methanolic
solution (15 mL) of FeCl36H2O (750 mg, 2.78 mmol) to a methano-
lic solution (5 mL) of bcmp (532 mg, 1.37 mmol) and adjusting the
pH to 5.8 with NaOH. The clear, purple solution was stirred for 5 h
at r.t. Addition of 75 mL of Et2O afforded the precipitation of a pur-
ple solid which was isolated by filtration, washed 3 times with
20 mL of diethyl ether and dried overnight under high-vacuum.
Unfortunately all attempts to obtain crystals suitable for X-ray
analysis failed. Yield: 675 mg (1.02 mmol, 75%). Anal. Calc. (%) for
C21H38Cl4Fe2N6O2: C, 38.21; H, 5.80; N, 12.73. Found: C, 38.84; H,
5.45; N, 12.46. ESI-MS (–): m/z 657.04 corresponding to
[Fe2{bcmp(-H)}(l-OH)(OH)2Cl3)].
2.3. Potentiometric titration
An aqueous solution of 2 (1 mM, 100 mL) was titrated with a
standardized 0.1 M NaOH solution at 25 C. Water was boiled to
remove any trace of CO2. The ionic strength was maintained at
0.1 M with KNO3. pH values were measured with a Jenway 3510
pH meter fitted with a Refex Sensor Ltd. EC-1910-11 glass elec-
trode. The program HYPERQUAD was used to calculate the deprotona-
tion constant from the titration data [17].
2.4. UV kinetic measurements
The hydrolysis rates of BDNPP were measured by monitoring
the increase in the visible absorbance at 400 nm due to the releaseof the 2,4-dinitrophenolate anion. Rate constants were obtained by
the initial rate method (<5% conversion). Concentrations of 2,4-
dinitrophenolate were calculated from the extinction coefficients
(12,100 M1cm1). Concentrations were corrected for the degree
of ionization of 2,4-dinitrophenol at the respective pH value using
pKa (2,4-dinitrophenol) = 4.0 [18]. In a typical experiment 15 lL of
a freshly prepared BDNPP stock solution (5 mM in DMSO) was
added to a solution of 2 (1.5 mL, 0.25–5 mM) at 40 C. The metal
complex solutions were buffered with 50 mM PIPBS (pH 3.5–5),
MES (pH 5–6.7), HEPES (pH 6.8–8.5) and CHES (pH 8.5–11.0). The
ionic strength was maintained at 0.1 M with KNO3. Hydrolysis
rates for BDNPP have been corrected for the spontaneous hydroly-
sis of the substrate [16]. Kinetic runs were run in duplicate to give
a reproducibility of ±8%.
Electronic spectra were recorded in H2O (5 mM) at different pH
values (2.5, 5.0, 7.5 and 9.0) using the same buffer solution and the
same ionic strength described before in this section.
2.5. Mössbauer spectroscopy
The RT Mössbauer spectrum was acquired on a sample of about
50 mg 2 mixed with vaseline. The hyperfine parameters isomer
shift (d), quadrupole splitting (D) and half linewidth at half maxi-
mum (C1/2), expressed in mm s1 were obtained by means of stan-
dard least-squares minimization techniques. The spectrum was
fitted to Lorentzian line shapes with the minimum number of sex-
tets and doublets. The isomeric shift is quoted relative to metallic
iron at RT.
2.6. Cyclic voltammetry
Cyclic voltammograms were recorded using a PalmSens EmS-
tat3+ potentiostat coupled to a single compartment electrochemi-
cal cell containing a Ag/AgCl (3 M KCl) reference electrode, a
platinumwire counter electrode (Goodfellow, UK) and a glassy car-
bon working electrode (BAS). Voltammograms were recorded in
pH 2.5, pH 5 (both 50 mM citrate buffer), pH 7.5 (50 mM phos-
phate buffer) and pH 10.2 (50 mM CAPS) buffered solutions.
2.7. DNA-binding experiments; UV–Vis absorption titration
Absorption titration experiments were performed by maintain-
ing a fixed CT-DNA concentration (0.14 mM) in Tris–HCl buffer and
increasing the concentration of 2 (producing reaction mixtures
with varied mole ratio of complex to CT-DNA; range from 0.1 to
1). The reference solution was the corresponding Tris–HCl buffer
solution. The sample solutions were scanned in the range
200–500 nm on a computer-controlled Varian Coulter DU 800
spectrophotometer.
2.8. pUC19 DNA cleavage activity
The DNA cleavage ability of 2was evaluated by agarose gel elec-
trophoresis. DNA plasmid pUC19 (1 lg/lL) was incubated with
increasing concentration (range 10–100 lM) of 2 in Tris buffer
(50 mM Tris, 18 mM NaCl, pH 8.2) in the absence and in the pres-
ence of an endogenous reductant (ascorbic acid) at 37 C for 3 h in
the dark. The reaction was quenched by the addition of 3 lL of
loading buffer (0.25% bromophenol blue and 30% glycerol), and
samples were loaded onto a 1% agarose gel in TBE buffer (89 mM
Tris, 89 mM boric acid, 2 mM EDTA, pH 8.2). The gels were sub-
jected to electrophoresis for 4 h at 50 V, followed by staining with
0.5 lg/mL ethidium bromide overnight. Gel bands were visualized
using a UV transilluminator and photographed using an Olympus
digital camera.
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Compound 2 was dissolved in DMSO just before the experi-
ment, and a calculated amount of drug solution was added to the
cell growth medium to a final solvent concentration of 0.5%, which
had no detectable effect on cell killing. Cisplatin was dissolved in
0.9% sodium chloride solution. MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) and cisplatin were obtained
from Sigma Chemical Co, St. Louis, USA.
2.9.1. Cell cultures
Human lung (A549) and pancreatic (BxPC3) carcinoma cell lines
along with melanoma (A375) cells were obtained from American
Type Culture Collection (ATCC, Rockville, MD). Human ovarian can-
cer cell lines 2008 were kindly provided by Prof. G. Marverti
(Department of Biomedical Science of Modena University, Italy).
Human cervical carcinoma cells A431 were kindly provided by
Prof. F. Zunino (Division of Experimental Oncology B, Istituto
Nazionale dei Tumori, Milan, Italy). LoVo human colon-carcinoma
cell lines were kindly provided by Prof. F. Majone (Department of
Biology of Padova University, Italy). Cell lines were maintained in
the logarithmic phase at 37 C in a 5% carbon dioxide atmosphere
using the following culture media containing 10% fetal calf serum
(Euroclone, Milan, Italy), antibiotics (50 units/mL penicillin and
50 lg/mL streptomycin), and 2 mM L-glutamine: (i) RPMI-1640
medium (Euroclone) for A431, 2008 and BxPC3 cells; (ii) F-12
HAM’S (Sigma Chemical Co.) for LoVo and A549 cells; (iii) DMEM
(Sigma Chemical Co.) for A375 cells.
2.9.2. MTT assay
The growth inhibitory effect toward tumor cells was evaluated
by means of MTT assay [19]. Briefly, (3–8)  103 cells/well, depen-
dent upon the growth characteristics of the cell line, were seeded
in 96-well microplates in growth medium (100 lL). After 24 h,
the medium was removed and replaced with fresh media contain-
ing the compound to be studied at the appropriate concentration.
Triplicate cultures were established for each treatment. After
72 h, each well was treated with 10 lL of a 5 mg/mL MTT saline
solution, and following 5 h of incubation, 100 lL of a sodium dode-
cylsulfate (SDS) solution in HCl (0.01 M) was added. After an over-
night incubation, cell growth inhibition was detected by measuring
the absorbance of each well at 570 nm using a Bio-Rad 680 micro-
plate reader. The mean absorbance for each drug dose was
expressed as a percentage of the control untreated well absorbance
and plotted versus drug concentration. IC50 values, the drug con-
centrations that reduce the mean absorbance at 570 nm to 50%
of those in the untreated control wells, were calculated by a four
parameter logistic (4-PL) model.Fig. 1. RT Mössbauer spectrum of the di-Fe(III) complex. Black dots: experimental
data, blue line: calculated spectrum. (For interpretation of the references to color in
this figure legend, the reader is referred to the web version of this article.)3. Results and discussion
3.1. Synthesis and spectroscopic characterization
The di-iron(III) complex of composition [Fe2{bcmp(-H)}(l-OH)
Cl2]Cl2 (2) has been obtained after addition of diethyl ether to a
methanolic solution of FeCl3 and the ligand bcmp in a 2:1 ratio
as shown in Chart 1. Unfortunately, several attempts to obtain
crystals suitable for X-ray analysis, including exchanging the
counter anion with perchlorate of hexcafluorophosphate, were
unsuccessful. The solid has been characterized by elemental anal-
ysis, Mössbauer spectroscopy, UV–Vis spectroscopy, pH potentio-
metric titration, ESI mass spectrometry and cyclic voltammetry.
RT Mössbauer spectroscopic investigations confirmed the
presence of only Fe(III) centers (Fig. 1). No signals attributable to
Fe(II) species were detected. The best fitting was obtained by usinga single doublet. The parameters (d: 0.36 mm/s and D: 0.76 mm/s)
are compatible with high spin octahedral Fe(III) (d: 0.36 mm/s and
D: 0.76 mm/s). The rather largeC1/2 value, 0.28 mm/s, is consistent
with literature data for similar complexes [13,20–22]. On the basis
of the experimental data the presence of two equivalent Fe(III)
sites can be supposed.
In aqueous solution the two chlorido ligands are replaced by
water ligands as confirmed by the ESI mass spectrum where the
peak in the negative mode at m/z = 657.04 corresponds to the spe-
cies {[Fe2{bcmp(-H)}(l-OH)(OH)2](Cl3)} (Fig. S1). The potentio-
metric pH titration of the complex was conducted in H2O and
the results confirm the presence of two molecules of water bound
to each Fe. From the titration curve it is clear that there are three
deprotonation steps which require three equivalents of NaOH in
the pH range between 2 and 11 (Fig. S2). The fitting of the titration
data gave the three pKa values of 2.70 ± 0.09, 6.84 ± 0.07 and
8.32 ± 0.09. These values are in good agreement with those
reported by Neves and co-workers for a similar di-iron complex
(2.90, 6.25 and 7.56) and correspond to the deprotonation of the
three molecules of water bound to the two Fe atoms [15]. In partic-
ular the first pKa1 (2.70) can be attributed to the deprotonation of
the bridging H2O to form the complex [Fe2{bcmp(-H)}(l-OH)
(OH2)2]Cl4 (2b); pKa2 corresponds to the deprotonation of one ter-
minal H2O molecule to form [Fe2{bcmp(-H)}(l-OH)(OH(OH2)]Cl3
(2c) and pKa3 to the deprotonation of the second terminal H2O
(2d, Chart 2).
UV–Vis spectra of 2 in aqueous buffer solutions were recorded
at different pH values (Fig. S3). In acidic solution (pH 2.5), when
species 2a is predominant, the spectrum shows a defined band at
557 nm which can be assigned to a LMCT (Ligand to Metal Charge
-1.0 -0.5 0.0 0.5 1.0
V (vs. Ag/AgCl)
D
C
B
A
Fig. 2. Cyclic voltammograms of 2 recorded in pH 2.5 (A), pH 5 (B), pH 7.5 (C) and
pH 10.2 (D) aqueous buffer solutions at a glassy carbon electrode. Arrows indicate
direction of scan; anodic current positive, scan rate: 0.1 V s1. Inset: Pourbaix plot
of cathodic peak potentials (Epc) against pH.
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to a very slight change in the electronic spectrum only (kmax at
pH 5.0 = 550 nm), but a remarkable shift can be observed after
passing to 2c and to 2dwhen the kmax moves to significantly lower
wave lengths (kmax at pH 7.5 and 9.0 = 535 nm and 490 nm, respec-
tively). This blue-shift (D = 22 and 67 nm, respectively) can be
attributed to the fact that in 2c and 2d the Lewis acidity of the
Fe(III) centers is lower and the t2g orbitals of these species have
higher energies with respect the t2g orbitals of 2a and 2b.
Voltammetric analysis of 2 was performed in order to evaluate
the redox properties of the complex over a broad pH range. Fig. 2
shows cyclic voltammograms (CVs) recorded for 2 in aqueous
media at pH values of 2.5, 5, 7.5 and 10.2. At pH 2.5 the dimer com-
plex is expected to be in the fully protonated form (species 2a). At
this pH the complex displays a cathodic peak potential (Epc) of
0.182 V and an anodic peak potential (Epa) of +0.84 V versus
Ag/AgCl indicative of an irreversible redox process [23]. The origin
of the reduction and oxidation peaks is likely due to the reduction
and subsequent oxidation of the Fe dimer metal center(s) as
observed for analogous oxoiron [15], oxoruthenium [24] and oxo-
manganese [25,26] dimer complexes. Epc peak potentials decrease
linearly with increase of pH at a rate of 0.067 V per pH unit (inset,
Fig. 2) close to a theoretical value of 0.059 V per pH unit pre-
dicted for a proton coupled or dependent electron transfer [27].
This reflects the successive electron coupled de-protonation of
the bridging and terminal water ligands at pH values greater than
pKa1, pKa2 and pKa3 in alignment with the potentiometric titration
analysis.
3.2. DNA binding
The binding modes of 2 to DNA were characterized through
electronic absorption titration and the representative UV–Vis spec-
trum in the presence of constant CT-DNA concentration is depicted
in Fig. 3. Upon increasing the complex/CT-DNA molar ratio (r) from
0.1 to 1, an increase in the absorption intensities (hyperchromism)
was observed. Hypochromism can result from a contraction of DNA
helix axis as well as from a change in conformation of the DNA.
However, our results clearly showed that no change in the position
of the absorption bands of the complex in the presence of DNA
occurred, thus suggesting the possibility of electrostatic andNH
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Chart 2. Proposed equilibria of complex 2.
Fig. 3. Spectra of solutions containing CT-DNA (0.14 mM) and increasing concen-
trations of complex 2 in Tris–HCl buffer, pH 8.1.groove (surface) binding of the metal complex outside the DNA
helix, either in the major or minor groove. In particular, we can
speculate that the hyperchromic effect could arise due to the
non-covalent, electrostatic interaction between the positively
charged complex moiety with extended hydrophobic region or sur-
faces and the negatively charged phosphate backbone of the dou-
ble helix CT-DNA, thereby causing a contraction and an overall
change of the secondary structure of DNA. In tris–HCl buffer (pH
8.1) the complex has an overall charge of 3+.
3.3. DNA cleavage and phosphate diester hydrolysis (BDNPP)
The DNA cleavage activity of the complex was monitored by
agarose gel electrophoresis using supercoiled pUC19 plasmid
DNA. The cleavage ability was measured as the conversion of DNA
Fig. 5. Dependence of the hydrolysis rate of BDNPP (5  105 M) on the concen-
tration of 2 at pH 7.0 (50 mM HEPES) and 40 C. I = 0.1 M (KNO3). Inset: The
Lineweaver–Burk double-reciprocal plot.
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nicked-circular form (NC, form II). SC pUC19 DNA (1 lg/mL) was
incubated with increasing complex concentrations (range 10–
100 lM) for 3 h in the absence and in the presence of an endoge-
nous reductant (ascorbic acid, 0.5 mM). Fig. S4 shows representa-
tive gel electrophoresis patterns resulting from the incubation of
SC-DNA with 10 and 100 lM solutions of the complex with and
without ascorbic acid. As shown in Fig. S4, no prominent DNA cleav-
age was observed for the complex in the absence of ascorbic acid
(lane 2 and 3). Conversely, treatment with complex 2 in combina-
tion with the reductant resulted in a concentration-dependent
cleavage of DNA. Under this condition, even at the lowest concen-
tration (lane 4), the complex was able to convert SC-DNA into the
NC form, whereas at 100 lM (lane 5), it cleaved DNA completely
(absence of the SC form). Ascorbic acid is a typical reducing agent
that is used to reduce Fe(III) to Fe(II) which is then responsible for
the oxidative cleavage of DNA probably via ROS formation.
Complex 2 mediates oxidative cleavage of DNA as most Fe(III)
complexes [28], but a few examples of Ferric complexes that hydro-
lyze DNA have been reported as well [29–32]. Therefore, we
thought it of interest to explore the potential of 2 to mediate phos-
phate ester hydrolysis using BDNPP (bis(2,4-dinitrophenyl) phos-
phate) which is a widely used model for the phosphodiester
linkages in DNA. 2-mediated BDNPP hydrolysis was monitored by
following the increase in the visible absorbance at 400 nm because
of the release of 2,4-dinitrophenolate. The dependence of the reac-
tion rate of BDNPP cleavage on the pH value in the presence of 2was
studied over the pH range 4.0–10.0. The plot of the pseudo-first-
order rate constants versus pH (Fig. 4) revealed a bell shaped profile
with a maximum value at pH 7.0, i.e. close to the midpoint between
pKa2 and pKa3 (pH 6.91). This behavior is completely different from
the analogs Zn2 and Cu2 complexes reported by us which showed
sigmoidal curves [11,12]. The dependence of the hydrolysis rate
on the concentration of the Fe complex (pH 7.0, 40 C) is displayed
in Fig. 5. The plot of the initial rate v0 versus complex concentration
revealed saturation kinetics and the linear Lineweaver–Burk plot
(inset, Fig. 5) indicatedMichaelis–Menten behavior with the forma-
tion of a kinetically active complex-substrate intermediate. From
the Lineweaver–Burk plot, the hydrolysis rate of the bound sub-
strate, kcat = 3.56  104 s1, and the substrate binding constant,
Km = 0.56 mM, were obtained. These values indicate a good cat-
alytic activity and a moderate binding affinity of BDNPP for 2 and
are in line with other dinuclear Fe(III) complexes reported in the lit-
erature [29–31]. Based on the kinetic data we propose the mecha-
nism shown in Chart 3 for the hydrolysis of BDNPP by 2. The2
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Fig. 4. Rate-pH profile for the cleavage of BDNPP (5  105 M) in the presence of 2
(1 mM) at 40 C. [buffer] = 50 mM (buffer = PIPBS (pH 3.5–5), MES (pH 5–6.7),
HEPES (pH 6.8–8.5), and CHES (pH 8.5–10.0); I = 0.1 M (KNO3).maximum in the rate-pH profile coincides with the pH value at
which the concentration of 2c is highest, suggesting that 2c is the
active species. The water ligand in 2c is the labile site where the
phosphate diester can bind to the Fe2 complex, while the hydroxido
ligand on the second Fe acts as the nucleophile.3.4. Cytotoxicity
The cytotoxic properties of 2 were evaluated against a panel of
human tumor cell lines containing examples of colorectal (LoVo),
pancreatic (BxPC3), cervical (A431), lung (A549), and ovarian
(2008) cancers as well as of melanoma (A375). For comparison
purposes, the cytotoxicity of cisplatin, the most widely used
metal-based anticancer drug, was evaluated under the same exper-
imental conditions. IC50 values, calculated from the dose-survival
curves obtained after 72 h of drug treatment from the MTT assay,
are shown in Table 1. Although on average the cytotoxic potency
shown by 2 was lower than that of cisplatin against four of the
tested tumor cell lines belonging to the in-house cell panel, the
dimetallic Fe(III) complex retained a significant in vitro antitumor
activity against LoVo cancer cells and against A375 melanoma
cells. Remarkably, the IC50 values calculated for 2 in colon cancer
cells was roughly 2.5 times lower than that of the reference metal-
lodrug cisplatin whereas against melanoma cells the toxicity was
comparable to that of cisplatin.NH
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Chart 3. Proposed mechanism of hydrolysis of BDNPP.
Table 1
Cytotoxic activity. Cells (3–5  104 ml1) were treated for 72 h with increasing
concentrations of 2 or cisplatin. Cell viability was evaluated by means of MTT test.
IC50 values were calculated by the dose–response curves by means of four parameter
logistic model (p < 0.05). SD = standard deviation.
Cell lines IC50, [lM] ± SD
Cisplatin 2
LoVo 8.53 ± 1.14 3.54 ± 0.97
BxPC3 11.13 ± 2.36 24.89 ± 2.75
A431 1.65 ± 0.51 14.08 ± 2.09
A375 1.89 ± 0.85 2.01 ± 0.77
A549 9.98 ± 2.86 25.61 ± 4.48
2008 2.22 ± 1.03 13.55 ± 7.81
T. Pinheiro Araujo et al. / Inorganica Chimica Acta 452 (2016) 170–175 1754. Conclusions
[Fe2{bcmp(-H)}(l-OH)Cl2]Cl2 is a novel dinuclear Fe(III) com-
plex which interacts with CT-DNA via electrostatic interaction
between the high positive charge (at pH 8.1, tris–HCl buffer, 2 is
3+) and the negative charges of the DNA phosphate groups. The
complex oxidatively cleaves pUC19 plasmid DNA in the presence
of ascorbic acid while hydrolytic cleavage is observed with the
model DNA phosphate ester BDNPP. Cytotoxicity studies revealed
an interesting activity in particular against a human colon cancer
cell line. Taken together, these results suggest that the in vitro anti-
tumor activity of 2 could be attributed to its DNA binding ability,
thus supporting the hypothesis that the molecular mechanism
and cytotoxic potential of [Fe2{bcmp(-H)}(l-OH)Cl2]Cl2, is related
to DNA cleavage ability. However, further in-cell experiments are
needed, in order to fully characterize molecular determinants
accounting for its antitumor potential.
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